BioWorld

March 23, 2005

GSK Licenses Another Program As Part Of Theravance Alliance

Theravance Inc. could receive in excess of $252 million under terms of a new license agreement with a familiar partner, GlaxoSmithKline plc. (BioWorld Today) Read More

Gilead Licenses HIV Integrase Inhibitor From Japan Tobacco

Scottish Scientists Search For Stem Cell Applications

VCs Debate Pros, Cons Of U.S. Investment In European Firms

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...